GlaxoSmithKline Pharmaceuticals Receives Rs 2.01 Crore TDS Demand Order from Tax Authority
GlaxoSmithKline Pharmaceuticals Limited has received a TDS demand order of Rs 2.01 crores from the tax authority for assessment year 2020-21, comprising Rs 1.11 crores in TDS and Rs 0.90 crores in interest. The company plans to contest the order through an appeal and states no immediate impact on financial statements.
*this image is generated using AI for illustrative purposes only.
GlaxoSmithKline Pharmaceuticals Limited has informed stock exchanges about receiving a final order from the TDS Authority imposing a demand liability of Rs 2.01 crores. The pharmaceutical company disclosed this development under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
TDS Demand Details
The demand order pertains to the assessment year 2020-21 and was issued by the TDS Authority – INT Tax Circle 2(3)(2). The total liability breaks down into two components: Rs 1.11 crores in TDS demand and Rs 0.90 crores in interest charges.
| Parameter | Details |
|---|---|
| Issuing Authority | TDS Authority – INT Tax Circle 2(3)(2) |
| Total Demand | Rs 2.01 crores |
| TDS Component | Rs 1.11 crores |
| Interest Component | Rs 0.90 crores |
| Assessment Year | 2020-21 |
| Order Date | 31st March, 2026 |
Nature of Assessment
The demand liability has been issued under TDS default provisions under Section 201 of the Income Tax Act. The assessment order was issued under Section 201(1)/201(1A) and was received by the company on 31st March, 2026.
Company's Response and Financial Impact
GlaxoSmithKline Pharmaceuticals has indicated it will contest the assessment order through appropriate legal channels. The company stated it is in the process of filing an appeal before the appellate authority to challenge the demand.
Regarding financial implications, the company has clarified that there will be no impact on its financial statements at this stage. This position is based on the company's decision to contest the assessment order through the appeals process.
Regulatory Compliance
The disclosure was made in compliance with stock exchange regulations, with the company informing both BSE Limited and the National Stock Exchange of India Limited about the development. The communication was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, ensuring proper corporate governance protocols were followed.
Historical Stock Returns for GlaxoSmithKline Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.76% | -0.44% | -10.11% | -14.30% | -17.37% | +61.40% |
What are the potential outcomes if GlaxoSmithKline's appeal is unsuccessful and how might this affect their tax compliance costs?
Could this TDS demand signal broader scrutiny of pharmaceutical companies' tax practices by Indian authorities?
How might prolonged legal proceedings impact GlaxoSmithKline's cash flow and operational planning in the coming quarters?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
